NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has appointed Hagop Youssoufian, M.Sc., M.D., Executive Vice President and Chief Medical Officer. In this position, Dr. Youssoufian will be responsible for the Company’s clinical product strategies, reporting to Jonathan Lewis, M.D., Ph.D., Chief Executive Officer of ZIOPHARM.
